PRESS RELEASE Arcadis 2025 Extraordinary General Meeting Arcadis’ shareholders appoint Robert Swaak to the Supervisory Board Amsterdam, 10 July 2025 – Arcadis (EURONEXT: ARCAD), the world’s leading company in delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, confirms that its shareholders appointed Robert Swaak to the company’s Supervisory Board for a four-year term. Robert Swaak will serve a four-year term, continuing through the 2029 annual Ge ...

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce the commencement of the second stage of laser-based ore sorting at the Company’s Bralorne Gold Project located in British Columbia (“Bralorne”). This next testing stage will consist of a run of mine test-work program using full scale equipment allowing for a direct comparison to full scale production projections and evaluate performance under economic conditions in ...

SAULT STE. MARIE, Ontario, July 10, 2025 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or the “Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced that it has achieved its first steel production at Unit One of its new, state-of-the-art electric arc furnace (“EAF”) project. The milestone follows over ten days of successful electric arc testing and tuning, including individual and tandem tests of all nine Q-One transfo ...

文章核心观点 Cytokinetics公司宣布在2025年欧洲心脏病学会大会上有五项关于aficamten的报告，包括MAPLE - HCM主要结果的热线报告和三项aficamten治疗梗阻性肥厚型心肌病临床试验中心房颤动发生率和影响的最新临床科学报告 [1] 分组1：会议报告信息 口头报告 - 报告“MAPLE - HCM: Aficamten vs Metoprolol in Obstructive HCM”由Pablo Garcia - Pavia博士于2025年8月30日上午9:18 CEST在马德里主礼堂进行 [2] - 报告“REDWOOD - HCM, SEQUOIA - HCM and FOREST - HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with Aficamten”由Ahmad Masri博士于2025年8月31日下午4:45 CEST在布达佩斯10号厅进行 [2] - 报告“Efficacy and Safety of Long - Term Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST - HCM”由Sara Saberi博士于2025年8月31日下午5:40 CEST在科学盒4（研究门户）进行 [2] 海报报告 - 报告“Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Pre - Specified Analysis of MAPLE - HCM”由Sheila Hegde博士进行，最终报告日期和时间待确认 [3] - 报告“Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis”由Ahmad Masri博士进行，最终报告日期和时间待确认 [3] 分组2：公司介绍 - 公司是一家专业心血管生物制药公司，在肌肉生物学领域有超25年的开创性科学创新，正在推进一系列治疗心肌功能障碍疾病的潜在新药管线 [4] - 公司正为aficamten的潜在监管批准和商业化做准备，该药是一种心肌肌球蛋白抑制剂，在梗阻性肥厚型心肌病的3期关键临床试验SEQUOIA - HCM中取得积极结果 [4] - 公司还在评估aficamten在其他梗阻性和非梗阻性肥厚型心肌病临床试验中的效果，同时正在开发omecamtiv mecarbil、CK - 586和CK - 089等药物 [4]

文章核心观点 - 在线博彩运营商Codere Online宣布将于2025年7月31日美国东部时间上午8:30前发布2025年第二季度财报，并于同日上午8:30举行电话会议讨论结果并提供业务更新 [1] 公司信息 Codere Online - 指Codere Online Luxembourg及其子公司，2014年作为Codere Group一部分推出 [3] - 通过先进网站和移动应用提供在线体育博彩和在线赌场服务，核心市场包括西班牙、墨西哥、哥伦比亚、巴拿马和阿根廷 [3] - 在线业务与Codere Group在拉丁美洲的实体业务互补，形成领先的全渠道博彩和赌场业务 [3] Codere Group - 跨国娱乐休闲集团，是私人博彩行业领先企业，有四十年经验 [4] - 在欧洲（西班牙和意大利）和拉丁美洲（阿根廷、哥伦比亚、墨西哥、巴拿马和乌拉圭）七个国家开展业务 [4] 财报及会议安排 - 2025年7月31日美国东部时间上午8:30前发布2025年第二季度财报 [1] - 同日上午8:30管理层将举行电话会议讨论结果并提供业务更新 [1] - 财报新闻稿和相关材料将在公司网站www.codereonline.com上提供 [2] - 电话会议拨号详情和网络直播注册链接可在同一网站的“活动与演示”部分获取，会议结束后将提供网络直播录音 [2] 联系方式 - 投资者和媒体联系Guillermo Lancha，邮箱Guillermo.Lancha@codere.com，电话(+34)-628-928-152 [5]

[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or t ...

RESTON, Va., July 10, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, has been selected by the U.S. Geological Survey (USGS) along with Colorado-based Merrick & Company to lead aerial lidar data collection in support of its 3D Elevation Program (3DEP), marking the latest in a series of federal task orders awarded under the multi-year Geospatial Products and Services Contract (GPSC4). 3DEP is a federal initiative to create the ...

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company’s CNSide Cerebrospinal Fluid (CSF) Assay Platform for patients at risk for central nervous system metastases HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherap ...

文章核心观点 - 2025年7月9日Cognition Therapeutics公司与美国FDA进行2期结束会议 讨论zervimesine（CT1812）2期研究结果和3期计划 有望推进其用于治疗阿尔茨海默病的开发 [1] 公司信息 - Cognition Therapeutics是临床阶段生物制药公司 致力于开发针对中枢神经系统年龄相关退行性疾病的小分子疗法 近期完成zervimesine（CT1812）在路易体痴呆、轻中度阿尔茨海默病和干性AMD继发地理萎缩的2期研究 早期阿尔茨海默病的2期START研究正在进行中 获美国国立卫生研究院8100万美元资助 [6] 药物信息 - zervimesine（CT1812）是每日口服一次的试验性药物 用于治疗阿尔茨海默病和路易体痴呆等中枢神经系统疾病 可中断Aβ和ɑ - 突触核蛋白的毒性作用 减缓疾病进展 临床研究中总体耐受性良好 美国USAN委员会已采用zervimesine作为CT1812的美国采用名 [2][3] 研究信息 - “SHINE”研究是双盲、安慰剂对照的2期研究 招募153名轻中度阿尔茨海默病成人患者 达到安全性和耐受性主要终点 还测量了认知和功能变化 参与者随机接受安慰剂或两种剂量的CT1812之一 每日口服 持续6个月 该研究获美国国立卫生研究院约3000万美元资助 [4][5]

VAL-D’OR, Quebec, July 10, 2025 (GLOBE NEWSWIRE) -- Cartier Resources Inc. (″ Cartier ″ or the ″ Company ″) (TSXV: ECR; FSE:6CA) is pleased to present its new predictive model for the Cadillac Project in the heart of the Val-d’Or mining camp, Quebec, created with Artificial Intelligence (″AI″) using VRIFY’s AI-Assisted Mineral Discovery Platform, DORA. With robust geoscientific information from across the 14,000-ha Cadillac Property, the Company was able to unlock value from this data by leveraging VRIFY’s ...